Ligand ID: PZI


Drugbank ID:
DB09210
(Piracetam)


Indication:
For the treatment of myoclonus (brief, involuntary twitching of a muscle or a group of muscles).

Get human targets for PZI in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'PZI' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5r7z 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.68A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.63A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.63A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A20.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.71A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6lze VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.79A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.76A21.86
None
DMS  A 403 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.69A21.86
None
DMS  A 403 (-4.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m17 RECEPTOR BINDING
DOMAIN
(SARS-CoV-2)		3 / 3
PRO F 507
SER F 438
ASN F 448
1.33A20.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D  10
SER B  10
GLY D  11
PRO D 122
1.60A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO A 122
SER A  10
ILE C 152
SER C  10
1.53A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER D 121
ILE B 152
PRO B   9
SER D 123
1.50A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO D 122
SER D  10
SER B  10
GLY D  11
1.67A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO B   9
GLY D 124
PRO D 122
SER D 147
1.63A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A  10
SER C  10
GLY A  11
PRO A 122
1.68A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO B 122
SER B 123
ASN B 119
1.63A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO B 122
SER B 123
ASN B  28
1.54A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.60A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE B 152
PRO B   9
SER D 123
SER D 121
1.48A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.52A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO B 122
SER B  10
ILE D 152
SER D  10
1.50A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C  10
SER A  10
GLY C  11
PRO C 122
1.61A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
TYR A 126
PRO A 122
SER A 123
SER A 147
1.79A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
PRO A   9
GLY C 124
PRO C 122
SER C 147
1.61A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE C 152
SER C  10
PRO A 122
SER A  10
1.56A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO C 122
SER C 123
ASN C  28
1.70A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER C 123
ASN C  28
SER C 147
GLY C 143
1.67A22.12

None
None
None
3WL  C 401 (-3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ILE D 152
SER D  10
PRO B 122
SER B  10
1.53A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER B  10
SER D  10
GLY B  11
PRO B 122
1.65A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2n 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO D 122
SER D 123
ASN D  28
1.70A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.64A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.73A22.12
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.65A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.53A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.62A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.69A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 536
PRO A 537
SER A 343
PRO A 378
1.57A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 6
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.68A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.66A20.54
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.52A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 7
ASN A 312
LEU A 469
ASP A 465
SER A 239
1.73A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.51A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.50A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 7
SER A 239
ASN A 312
LEU A 469
ASP A 465
1.75A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.64A14.77

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6m71 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.51A14.77
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C 816
ASP C 820
ASN C 824
1.26A12.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP B 820
ASN B 824
SER B 816
1.31A12.34
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO C 600
SER C 605
LEU C 296
ASP C 294
1.46A12.11
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6vxs NSP3
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP C 820
ASN C 824
SER C 813
0.71A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO A 600
SER A 605
LEU A 296
ASP A 294
1.57A12.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE C 587
PRO C 589
GLY C 550
ASN A 978
1.30A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
PRO B 579
SER B 530
ASN B 331
1.62A12.70
None
None
NAG  B1305 (-1.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP A 820
ASN A 824
SER A 813
0.74A12.70
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER C 813
ASP C 820
ASN C 824
0.77A12.62
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 324
ASN B  75
SER B 198
0.93A22.10
None
EDO  B 403 (-4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6w02 NSP3
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.65A19.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w37 PROTEIN 7A
(SARS-CoV-2)		4 / 8
SER A  21
GLY A  23
PRO A  19
ASN A  37
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w37 PROTEIN 7A
(SARS-CoV-2)		4 / 8
PRO A  19
ASN A  37
SER A  21
GLY A  23
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PRO C 507
SER C 443
ASN C 437
GLY C 502
1.63A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
PRO C 507
SER C 443
ASN C 501
GLY C 496
1.60A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		3 / 3
SER L  56
ASP C 389
ASN C 388
1.41A20.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
PRO H 100
ILE H  98
SER C 383
GLY H  97
1.77A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 SPIKE PROTEIN S1
(SARS-CoV-2)		4 / 8
GLY C 496
PRO C 507
SER C 443
ASN C 501
1.54A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER H  96
SER C 383
GLY H  97
1.61A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER H  96
SER C 383
GLY H  97
1.66A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB HEAVY
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		4 / 8
ILE H  98
SER C 383
GLY H  97
PRO H 100
1.79A19.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		3 / 3
ASP C 389
ASN C 388
SER L  56
1.32A21.80
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w4h NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.31A20.13
SAM  A7102 (-3.8A)
SAM  A7102 ( 4.5A)
BDF  B4403 (-3.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.34A
SAM  A7104 (-3.9A)
SAM  A7104 (-4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASN A7008
ILE A7079
PRO A6860
SER A6964
1.71A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN B  99
ILE B 131
SER B 128
GLY B 130
1.53A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.58A20.24
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B  99
1.58A20.24
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.67A20.24
None
None
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.69A20.24
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.69A20.24
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.64A20.24
None
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.73A20.24
None
AMP  A 201 ( 3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 133
PRO B 136
SER B 139
1.71A20.24
MES  B 201 ( 4.5A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 133
1.76A20.24
None
None
MES  B 201 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 133
PRO A 136
SER A 139
1.76A20.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.38A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.42A20.24
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.52A20.24
None
None
MES  B 201 ( 4.5A)
MES  B 201 ( 3.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w6y NSP3
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.65A20.24
None
AMP  A 201 ( 3.6A)
None
AMP  A 201 ( 3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.63A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.70A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C6838
PRO C6835
SER C7039
SER C7041
1.71A18.25
None
None
FMT  C7111 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO C6878
SER C6872
ASN D4293
1.26A18.25
SAM  C7105 ( 3.9A)
SAM  C7105 ( 4.4A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ILE C6838
PRO C6835
SER C7039
SER C7041
1.70A18.25
None
None
FMT  C7111 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASN A7008
ILE A7079
PRO A6860
SER A6964
1.72A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASN C7008
ILE C7079
PRO C6860
SER C6964
1.71A18.25
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6w75 NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.29A18.25
SAM  A7102 ( 3.8A)
SAM  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR B 305
MET B 244
SER B 245
SER B 262
1.67A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A  56
MET A  84
SER A  85
LEU A  80
1.76A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR C 251
PRO C 247
SER C 245
LEU C 211
1.80A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR C 305
MET C 244
SER C 245
SER C 262
1.69A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 305
MET A 244
SER A 245
SER A 262
1.64A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9c PAPAIN-LIKE
PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 251
PRO A 247
SER A 245
LEU A 211
1.72A23.19
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6w9q 3C-LIKE PROTEINASE
PEPTIDE, NSP9 FUSION
(SARS-CoV-2)		4 / 8
TYR A  31
SER A  13
SER A  46
LEU A  45
1.72A17.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.33A
None
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.51A
None
None
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.55A
None
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.36A
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.55A
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wcf NSP3
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.60A
MES  A 201 (-4.1A)
MES  A 201 (-4.4A)
MES  A 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6wen NSP3
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.61A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wen NSP3
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
ILE A 335
SER A 332
GLY A 334
ASN A 303
1.47A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
SER A 332
GLY A 337
PRO A 340
SER A 343
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
PRO A 340
SER A 343
SER A 332
GLY A 334
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wey NSP3
(SARS-CoV-2)		4 / 8
ASN A 303
ILE A 335
SER A 332
GLY A 334
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO D 309
ILE D 337
SER D 318
GLY D 335
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO C 309
ILE C 337
SER C 318
GLY C 335
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO E 302
LEU E 291
ASP E 288
LYS E 355
1.51A16.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO A 309
ILE A 337
SER A 318
GLY A 335
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO D 302
LEU D 291
ASP D 288
LYS D 355
1.60A16.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE A 337
SER A 318
GLY A 335
PRO A 309
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE C 337
SER C 318
GLY C 335
PRO C 309
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE B 337
SER B 318
GLY B 335
PRO B 309
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE D 337
SER D 318
GLY D 335
PRO D 309
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE F 337
SER F 318
GLY F 335
PRO F 309
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO F 309
ILE F 337
SER F 318
GLY F 335
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO E 309
ILE E 337
SER E 318
GLY E 335
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO B 309
ILE B 337
SER B 318
GLY B 335
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wji NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE E 337
SER E 318
GLY E 335
PRO E 309
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.40A
SAH  A7102 (-3.8A)
SAH  A7102 ( 4.6A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.63A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE C 157
SER C  51
PRO C  73
ASN D  77
1.34A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO C  73
ASN D  77
ILE C 157
SER C  51
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
PRO A  73
ASN B  77
ILE A 157
SER A  51
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkp NUCLEOCAPSID PROTEIN
(SARS-CoV-2)		4 / 8
ILE A 157
SER A  51
PRO A  73
ASN B  77
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.34A
SFG  A7103 ( 3.8A)
SFG  A7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 6
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.78A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP10
NSP16
(SARS-CoV-2)		3 / 3
PRO C6878
SER C6872
ASN D4293
1.32A
SFG  C7103 ( 3.9A)
SFG  C7103 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE A6838
PRO A6835
SER A7039
SER A7041
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 8
ILE C7079
PRO C6860
SER C6964
ASN C7008
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 7
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.75A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA800_0
(GLUTAMATE RECEPTOR 2)		6wkq NSP16
(SARS-CoV-2)		4 / 7
MET A6863
ASN C7096
LEU A6892
ASP A6906
1.79A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 198
ASP A 273
ASN A  74
1.42A
None
EDO  A 408 (-3.0A)
EDO  A 406 (-4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ILE A 236
GLY A 248
PRO A 344
SER A 294
1.66A
None
U5P  A 401 ( 4.5A)
None
U5P  A 401 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PRO A 344
SER A 294
ILE A 236
GLY A 248
1.66A
None
U5P  A 401 (-2.7A)
None
U5P  A 401 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ILE B 236
GLY B 248
PRO B 344
SER B 294
1.65A
None
U5P  B 401 ( 4.4A)
None
U5P  B 401 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP A 273
ASN A  74
SER A 198
1.37A
EDO  A 408 (-3.0A)
EDO  A 406 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP A 324
ASN A  75
SER A 198
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 198
ASP B 273
ASN B  74
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PRO B 344
SER B 294
ILE B 236
GLY B 248
1.66A
None
U5P  B 401 (-2.7A)
None
U5P  B 401 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER A 198
ASP A 324
ASN A  75
0.95A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 324
ASN B  75
SER B 198
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
SER B 198
ASP B 324
ASN B  75
0.94A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		3 / 3
ASP B 273
ASN B  74
SER B 198
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.54A
None
None
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE D 131
SER D 128
GLY D 130
ASN D 101
1.65A
APR  D 201 (-3.8A)
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.56A
None
None
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER D 128
GLY D 130
PRO D 136
SER D 139
1.58A
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.59A
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.51A
APR  B 201 (-3.3A)
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.53A
None
None
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.59A
None
APR  A 201 (-3.8A)
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.59A
APR  C 201 (-3.9A)
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.54A
None
None
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.61A
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.63A
APR  A 201 (-3.8A)
APR  A 201 (-4.4A)
APR  A 201 (-3.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.55A
None
APR  C 201 (-3.9A)
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.48A
None
APR  B 201 (-3.3A)
APR  B 201 (-4.5A)
APR  B 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.58A
APR  C 201 (-4.4A)
APR  C 201 (-3.0A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 7
SER A6943
ASN A6975
LEU A6978
ASP A6977
1.78A20.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		3 / 3
PRO A6878
SER A6872
ASN B4293
1.35A
SAH  A7101 (-3.9A)
SO4  A7109 (-4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ILE A7079
PRO A6860
SER A6964
ASN A7008
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6wrh PEPTIDASE C16
(SARS-CoV-2)		4 / 8
TYR A 305
MET A 244
SER A 245
SER A 262
1.73A23.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.77A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.66A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A  28
SER A 123
SER A 121
GLY A 124
1.67A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 123
SER A 121
GLY A 124
ASN A  28
1.65A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
ILE A  34
PRO A  33
SER A  38
ASN A  37
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yi3 NUCLEOPROTEIN
(SARS-CoV-2)		4 / 8
ASN A  37
ILE A  34
PRO A  33
SER A  38
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO A 507
SER A 443
ASN A 501
GLY A 496
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE E 332
PRO E 330
SER E 366
PRO E 527
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLY A 496
PRO A 507
SER A 443
ASN A 501
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ILE E 332
PRO E 330
PRO E 527
SER E 366
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
SER A 514
ASP A 398
ASN A 354
1.62A
None
None
PG0  A 902 ( 4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
PRO E 527
SER E 366
ILE E 332
PRO E 330
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		3 / 3
ASP A 398
ASN A 354
SER A 514
1.63A
None
PG0  A 902 ( 4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.63A
None
P6N  A 502 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.63A
None
None
None
P6N  A 502 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		6yor IGG H CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		4 / 8
TYR E 453
PRO B  14
SER B  85
LEU E 455
1.73A22.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
GLY E 496
PRO E 507
SER E 443
ASN E 501
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A 119
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.59A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP E 162
ASN E 159
SER E 166
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER D 166
ASP D 162
ASN D 159
1.61A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.13A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 157
ASN D  20
SER C  84
1.12A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E   5
ASP D  14
ASN D  15
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B  99
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.66A
None
None
None
EDO  D 205 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B  99
ILE B 131
SER B 128
GLY B 130
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C  99
ILE C 131
SER C 128
GLY C 130
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.68A
None
None
EDO  A 202 (-4.3A)
EDO  A 202 ( 4.4A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E 166
ASP E 162
ASN E 159
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D  14
ASN D  15
SER E   5
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywk NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO E 136
SER E 139
SER E 128
GLY E 130
1.68A
None
None
EPE  E 202 (-4.6A)
EPE  E 202 ( 4.5A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER E 128
GLY E 130
PRO E 136
SER E 139
1.60A
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
EDO  B 202 (-4.7A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER B 128
GLY B 130
PRO B 136
SER B 139
1.58A
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.53A
None
None
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE D 131
SER D 128
GLY D 130
ASN D 101
1.54A
APR  D 201 (-3.4A)
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.57A
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.56A
APR  A 201 (-3.1A)
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO D 136
SER D 139
SER D 128
GLY D 130
1.53A
None
None
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE E 131
SER E 128
GLY E 130
ASN E 101
1.57A
APR  E 201 (-3.4A)
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER B 166
ASP B 162
ASN B 159
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE B 131
SER B 128
GLY B 130
ASN B 101
1.55A
APR  B 201 (-3.2A)
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.56A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D  14
ASN D  15
SER E   5
1.28A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP C 162
ASN C 159
SER C 166
1.58A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C  84
ASP D 157
ASN D  20
1.12A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.58A
APR  C 201 (-3.3A)
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP B 162
ASN B 159
SER B 166
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER D 128
GLY D 130
PRO D 136
SER D 139
1.57A
APR  D 201 (-4.3A)
APR  D 201 (-3.2A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER D 166
ASP D 162
ASN D 159
1.58A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN B 101
ILE B 131
SER B 128
GLY B 130
1.53A
None
APR  B 201 (-3.2A)
APR  B 201 (-4.3A)
APR  B 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.53A
None
None
APR  C 201 (-4.4A)
APR  C 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 162
ASN D 159
SER D 166
1.59A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO E 136
SER E 139
SER E 128
GLY E 130
1.55A
EDO  B 202 (-4.7A)
None
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP D 157
ASN D  20
SER C  84
1.11A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.59A
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
EDO  A 205 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN E 101
ILE E 131
SER E 128
GLY E 130
1.52A
None
APR  E 201 (-3.4A)
APR  E 201 (-4.4A)
APR  E 201 (-3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP E 162
ASN E 159
SER E 166
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E 166
ASP E 162
ASN E 159
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER E   5
ASP D  14
ASN D  15
1.17A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywl NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.54A
EDO  A 205 ( 4.9A)
None
APR  A 201 (-4.4A)
APR  A 201 ( 3.2A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C  99
ILE C 131
SER C 128
GLY C 130
1.66A
None
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER C 128
GLY C 130
PRO C 136
SER C 139
1.58A
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A 101
1.46A
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN A 101
ILE A 131
SER A 128
GLY A 130
1.42A
None
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN A  99
ILE A 131
SER A 128
GLY A 130
1.56A
None
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
SER A 128
GLY A 130
PRO A 136
SER A 139
1.56A
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO A 136
SER A 139
SER A 128
GLY A 130
1.51A
None
None
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO B 136
SER B 139
SER B 128
GLY B 130
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ASN C 101
ILE C 131
SER C 128
GLY C 130
1.48A
None
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER A 166
ASP A 162
ASN A 159
1.39A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
PRO C 136
SER C 139
SER C 128
GLY C 130
1.53A
None
None
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
SER C 166
ASP C 162
ASN C 159
1.57A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE A 131
SER A 128
GLY A 130
ASN A  99
1.60A
MES  A 201 (-4.8A)
MES  A 201 (-4.4A)
MES  A 201 (-3.1A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_E_PZIE802_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		3 / 3
ASP A 162
ASN A 159
SER A 166
1.37A20.08
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		6ywm NSP3 MACRODOMAIN
(SARS-CoV-2)		4 / 8
ILE C 131
SER C 128
GLY C 130
ASN C 101
1.53A
MES  C 201 (-4.0A)
MES  C 201 (-4.6A)
MES  C 201 (-3.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bqy MAIN PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.49A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 378
PRO A 328
SER A 664
GLY A 327
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 8
SER A 397
PRO B 121
SER A 672
GLY A 385
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
NSP8
(SARS-CoV-2)		4 / 8
PRO B 121
SER A 672
GLY A 385
SER A 397
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.72A14.89
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.06A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7btf NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.07A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		3 / 3
PRO A 122
SER A 123
ASN A  28
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
SER A 123
ASN A  28
SER A 147
GLY A 143
1.58A
None
None
None
JRY  A 401 (-3.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
SER A 147
GLY A 143
SER A 123
ASN A  28
1.60A
None
JRY  A 401 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.49A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.23A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 8
PRO B 121
SER A 672
GLY A 385
SER A 397
1.29A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv1 NSP12
NSP8
(SARS-CoV-2)		4 / 8
SER A 397
PRO B 121
SER A 672
GLY A 385
1.33A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
SER A 229
GLY A 200
PRO A 232
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_B_PZIB800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
TYR A 530
LEU A 527
PRO A 505
SER A 564
GLY A 503
1.59A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
NSP8
(SARS-CoV-2)		4 / 7
ASN B 109
LEU A 271
ASP A 269
LYS A 272
1.79A18.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 201
GLY A 230
PRO A 227
ASN A 198
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 539
PRO A 378
SER A 664
PRO A 537
1.03A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_G_PZIG801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		3 / 3
PRO A 243
SER A 239
ASN A 312
1.25A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 232
ILE A 201
SER A 229
GLY A 200
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 227
ASN A 198
ILE A 201
GLY A 230
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
MET A 756
SER A 759
LEU A 758
ASP A 761
1.77A14.87
None
U  P  20 ( 2.8A)
None
MG  P 101 (-3.0A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
PRO A 328
SER A 664
GLY A 327
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_D_PZID801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PRO A 537
ILE A 539
PRO A 378
SER A 664
1.04A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSF_H_PZIH800_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
MET A 633
SER A 635
LEU A 308
ASP A 304
1.66A14.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3LSL_A_PZIA801_0
(GLUTAMATE RECEPTOR 2)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ILE A 536
PRO A 537
SER A 343
PRO A 378
1.68A
None